Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy

Journal of Oral and Maxillofacial Surgery

Volumn 71, Issue 3, 2013, Pages 513-519

  Fleisher, Kenneth E ^a   Jolly, Anu ^b   Venkata, Uma Deepthi Chippada ^c   Norman, Robert G ^a   Saxena, Deepak ^a   Glickman, Robert S ^a  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^c POLYTECHNIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; DENTAL SURGERY; DENTURE; DRUG EXPOSURE; FEMALE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; PATIENT REFERRAL; RISK FACTOR; TOOTH EXTRACTION; TOOTH IMPLANT; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ORAL SURGICAL PROCEDURES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84874117624     PISSN: 02782391     EISSN: 15315053     Source Type: Journal    
DOI: 10.1016/j.joms.2012.07.049     Document Type: Article

References (82)

1. H. Kamel Update on osteoporosis in long-term care: Focus on bisphosphonates J Am. Med Dir Assoc 8 2007 434
2. R.E. Coleman Risks and benefits of bisphosphonates Br J Cancer 98 2008 1736
3. F. Saad New research findings on zoledronic acid: Survival, pain, and anti-tumour effects Cancer Treat Rev 34 2008 183
4. K.P. Weinfurt, L.D. Castel, and Y. Li Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions Med Care 42 2004 164
5. M. Gnant, B. Mlineritsch, and W. Schippinger Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 2009 679
6. P.A. Newcomb, A. Trentham-Dietz, and J.M. Hampton Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk Br J Cancer 102 2010 799
7. C. Schmidt New studies support case for bisphosphonates as possible chemopreventive agent J Natl Cancer Inst 102 2010 453
8. A.M. Brufsky Cancer treatment-induced bone loss: Pathophysiology and clinical perspectives Oncologist 13 2008 187
9. F. Davies, G. Morgan, and P. Wu Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC myeloma IX trial J Clin Oncol 29 suppl, abstr 2011 8011
10. S. Ruggiero, T. Dodson, and L. Assael American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update J Oral Maxillofac Surg 67 2009 2
11. S. Ruggiero, J. Gralow, and R.E. Marx Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer J Oncol Pract 2 2006 7
12. R. Rizzoli, N. Burlet, and D. Cahall Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis Bone 42 2008 841
13. K. Fizazi, M. Carducci, and M. Smith A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer J Clin Oncol 28 abstr 2010 18s
14. K.H. Taylor, L.S. Middlefell, and K.D. Mizen Osteonecrosis of the jaws induced by anti-RANK ligand therapy Br J Oral Maxillofac Surg 48 2010 221
15. T.L. Aghaloo, A.L. Felsenfeld, and S. Tetradis Osteonecrosis of the jaw in a patient on denosumab J Oral Maxillofac Surg 68 2010 959
16. L.A. Assael How new knowledge sounds: Developing a contemporary understanding of osteonecrosis J Oral Maxillofac Surg 68 2010 957
17. S. Greuter, F. Schmid, and T. Ruhstaller Bevacizumab-associated osteonecrosis of the jaw Ann Oncol 19 2008 2091
18. S.A. Almazrooa, and S.B. Woo Bisphosphonate and nonbisphosphonate- associated osteonecrosis of the jaw: A review J Am Dent Assoc 140 2009 864
19. M. Kos, D. Brusco, and J. Kuebler Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration Int J Oral Maxillofac Surg 39 2010 1097
20. G. Saia, S. Blandamura, and G. Bettini Occurrence of bisphosphonate- related osteonecrosis of the jaw after surgical tooth extraction J Oral Maxillofac Surg 68 2010 797
21. P. Lesclous, S. Abi Najm, and J.P. Carrel Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation? Bone 45 2009 843
22. C.L. Estilo, M. Fornier, and A. Farooki Osteonecrosis of the jaw related to bevacizumab J Clin Oncol 28 2008 4037
23. P. Infante-Cossio, J.C. Lopez-Martin, and E. Gonzalez-Cardero Osteonecrosis of the maxilla associated with cancer chemotherapy in patients wearing dentures J Oral Maxillofac Surg 70 2012 1587
24. O. Filleul, E. Crompot, and S. Saussez Bisphosphonate-induced osteonecrosis of the jaw: A review of 2,400 patient cases J Cancer Res Clin Oncol 136 2010 1117
25. P. Diz, J. Limeres, and S. Fedele Is oral bisphosphonate-related osteonecrosis of the jaw an endemic condition? Med Hypotheses 78 2012 315
26. M.R. Allen, and D.B. Burr The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data J Oral Maxillofac Surg 67 2009 61
27. D.B. Burr ASBMR Task Force Summary of ASBMR Task Force on ONJ J Musculoskelet Neuronal Interact 7 2007 354
28. T. Ibrahim, F. Barbanti, and G. Giorgio-Marrano Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: A retrospective study Oncologist 13 2008 330
29. I. Diel, I. Fogelman, and B. Al-Nawas Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol/Hematol 64 2007 198
30. C.D. Krueger, P.M. West, and M. Sargent Bisphosphonate-induced osteonecrosis of the jaw Ann Pharmacother 41 2007 276
31. C.L. Estilo, C.H. van Poznak, and T. Wiliams Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy Oncologist 13 2008 911
32. C.A. Migliorati, J. Casiglia, and J. Epstein Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper J Am Dent Assoc 136 2005 1658
33. S. Fedele, N. Kumar, and R. Davies Dental management of patients at risk of osteochemonecrosis of the jaws: A critical review Oral Dis 15 2009 527
34. T.B. Dodson Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 67 2009 44
35. A. Bamias, E. Kastritis, and C. Bamia Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors J Clin Oncol 23 2005 8580
36. A. Badros, D. Weikel, and A. Salama Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors J Clin Oncol 24 2006 945
37. M.A. Dimopoulos, E. Kastritis, and A. Anagnostopoulos Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid Haematologica 91 2006 968
38. J.E. Fantasia Bisphosphonates - What the dentist needs to know: Practical considerations J Oral Maxillofac Surg 67 2009 53
39. V. Fusco, C. Galassi, and A. Berruti Osteonecrosis of the jaw after zoledronic acid and denosumab treatment J Clin Oncol 29 2011 e521
40. L.A. Assael Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: Clinical findings, assessment of risks, and preventive strategies J Oral Maxillofac Surg 67 2009 35
41. S. Otto, S. Hafner, and K.A. Grötz The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw J Oral Maxillofac Surg 67 2009 589
42. L. Junquera, and L. Gallego Nonexposed bisphosphonate-related osteonecrosis of the jaws: Another clinical variant? J Oral Maxillofac Surg 66 2008 1516
43. H. Mawardi, N. Treister, and P. Richardson Sinus tracts - An early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg 67 2009 593
44. M. Hutchinson, F. O'Ryan, and V. Chavez Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure J Oral Maxillofac Surg 68 2010 2232
45. V. Adamo, N. Caristi, and M.M. Saccà Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients Expert Opin Pharmacother 9 2008 1351
46. R.G. Russell, Z. Xia, and J.E. Dunford Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy Ann N Y Acad Sci 1117 2007 209
47. R.E. Marx, Y. Sawatari, and M. Fortin Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 63 2005 1567
48. S. Otto, S. Hafner, and G. Mast Bisphosphonate-related osteonecrosis of the jaw: Is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg 68 2010 1158
49. P.G. Morris, C. Hudis, and J. Carrasquillo Bone scans, bisphosphonates, and a lack of acute changes within the mandible J Oral Maxillofac Surg 69 2011 114
50. H.M. Weiss, U. Pfaar, and A. Schweitzer Biodistribution and plasma protein binding of zoledronic acid Drug Metab Dispos 36 2008 2043
51. B. Frieder, T. Pfister, and S. Papapoulos Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat J Bone Miner Metab 26 2008 406
52. I.R. Reid Osteonecrosis of the jaw: Who gets it, and why? Bone 44 2009 4
53. F. Bertoldo, D. Santini, and V. Lo Cascio Bisphosphonates and osteomyelitis of the jaw: A pathogenic puzzle Nat Clin Pract Oncol 4 2007 711
54. S.E. Papapoulos Bisphosphonate actions: Physical chemistry revisited Bone 38 2006 613
55. M. Pazianas Osteonecrosis of the jaw and the role of macrophages J Natl Cancer Inst 103 2011 1
56. A. Hokugo, R. Christensen, and E.M. Chung Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats J Bone Miner Res 25 2010 1337
57. J.D. Kassolis, M. Scheper, and B. Jham Histopathologic findings in bone from edentulous alveolar ridges: A role in osteonecrosis of the jaws? Bone 47 2010 127
58. T.J. Stewart, and M.J. Smyth Improving cancer immunotherapy by targeting tumor-induced immune suppression Cancer Metastasis Rev 30 2011 125
59. J.A. Toljanic, J.F. Bedard, and R.A. Larson A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer Cancer 85 1999 1843
60. J.E. Raber-Durlacher, J.B. Epstein, and J. Raber Periodontal infection in cancer patients treated with high-dose chemotherapy Support Care Cancer 10 2002 466
61. V. Breuil, M. Ticchioni, and J. Testa Immune changes in post-menopausal osteoporosis: The Immunos study Osteoporos Int 21 2010 805
62. N.H. Naik, and T.A. Russo Bisphosphonate-related osteonecrosis of the jaw: The role of actinomyces Clin Infect Dis 49 2009 1729
63. X. Ji, S. Pushalkar, and Y. Li Antibiotic effects on bacterial profile in osteonecrosis of the jaw Oral Dis 18 2012 85
64. P. Sedghizadeh, S. Kumar, and A. Gorur Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy J Oral Maxillofac Surg 66 2008 767
65. P.P. Sedghizadeh, S.K. Kumar, and A. Gorur Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy J Am Dent Assoc 140 2009 1259
66. W. Moore, and L. Moore The bacteria of periodontal disease Periodontol 5 1994 66
67. B.J. Paster, S.K. Boches, and J.L. Galvin Bacterial diversity in human subgingival plaque J Bacteriol 183 2001 3770
68. X. Wei, Pushalkar, and C. Estilo Molecular profiling of oral microbiota in jaw bone samples of bisphosphonate related osteonecrosis of the jaw Oral Dis 18 2012 602
69. N. Raje, S.B. Woo, and K. Hande Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw Clin Cancer Res 14 2008 2387
70. G.J. Domingue, and H.B. Woody Bacterial persistence and expression of disease Clin Microbiol Rev 10 1997 320
71. P.A. Mackowiak Microbial synergism in human infections (second of two parts) N Engl J Med 298 1978 83
72. P.A. Mackowiak Microbial synergism in human infections (first of two parts) N Engl J Med 298 1978 21
73. T. Nyström Nonculturable bacteria: Programmed survival forms or cells at death's door? Bioessays 25 2003 204
74. F. Fenollar, and D. Raoult Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria Int J Antimicrob Agents 30 suppl 2007 S7
75. J.F. Siqueira, and I.N. Rôças The microbiota of acute apical abscesses J Dent Res 88 2009 61
76. J.F. Siqueira, and I.N. Rôças Diversity of endodontic microbiota revisited J Dent Res 88 2009 969
77. R. Baron, S. Ferrari, and R.G. Russell Denosumab and bisphosphonates: Different mechanisms of action and effects Bone 48 2011 677
78. M. Kos, J.F. Kuebler, and K. Luczak Bisphosphonate-related osteonecrosis of the jaws: A review of 34 cases and evaluation of risk J Craniomaxillofac Surg 38 2010 255
79. A.O. Hoff, B.B. Toth, and K. Altundag Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 2008 826
80. O. Nicolatou-Galitis, E. Papadopoulou, and T. Sarri Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: Prospective experience of a dental oncology referral center Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112 2011 195
81. J.C. Lo, F.S. O'Ryan, and N.P. Gordon Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure J Oral Maxillofac Surg 68 2010 243
82. K. Vahtsevanos, A. Kyrgidis, and E. Verrou Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J Clin Oncol 27 2009 5356